Normal human kidney HLA-DR-expressing renal microvascular endothelial cells: Characterization, isolation, and regulation of MHC class II expression

Journal of the American Society of Nephrology

Volumn 14, Issue 5, 2003, Pages 1336-1348

  Muczynski, Kimberly A ^a   Ekle, David M ^a   Coder, David M ^a   Anderson, Susan K ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD31 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; HLA DR ANTIGEN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANTIGEN EXPRESSION; ARTICLE; ENDOTHELIUM CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; IN SITU HYBRIDIZATION; KIDNEY CELL; MICROVASCULATURE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN ISOLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE;

EID: 0037408418     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000061778.08085.9F     Document Type: Article

References (50)

1. Muczynski KA, Cotner T, Anderson SK: Unusual expression of human lymphocyte antigen class II in normal renal microvascular endothelium. Kidney Int 59: 488-497, 2001
2. Croft M, Dubey C: Accessory molecule and costimulation requirements for CD4 T cell response. Crit Rev Immunol 17: 89-118, 1997
3. Hagerty DT, Evavold BD, Allen PM: Regulation of the costimulator B7, not class II major histocompatibility complex, restricts the ability of murine kidney tubule cells to stimulate CD4+ T cells. J Clin Invest 93: 1208-1215, 1994
4. Singer GG, Yokoyama H, Bloom RD, Jevnikar AM, Nabavi N, Kelley VR: Stimulated renal tubular epithelial cells induce anergy in CD4+ T cells [see comments]. Kidney Int 44: 1030-1035, 1993
5. Steimle V, Otten LA, Zufferey M, Mach B: Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 75: 135-146, 1993
6. Steimle V, Siegrist CA, Mottet A, Lisowska-Grospierre B, Mach B: Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science 265: 106-109, 1994
7. Chang CH, Fontes JD, Peterlin M, Flavell RA: Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes. J Exp Med 180: 1367-1374, 1994
8. Steimle V, Durand B, Barras E, Zufferey M, Hadam MR, Mach B, Reith W: A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome). Genes Dev 9: 1021-1032, 1995
9. Masternak K, Barras E, Zufferey M, Conrad B, Corthals G, Aebersold R, Sanchez JC, Hochstrasser DF, Mach B, Reith W: A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients. Nat Genet 20: 273-277, 1998
10. Nagarajan UM, Louis-Plence P, DeSandro A, Nilsen R, Bushey A, Boss JM: RFX-B is the gene responsible for the most common cause of the bare lymphocyte syndrome, an MHC class II immunodeficiency [published erratum appears in Immunity 1999 Mar; 10(3): 399]. Immunity 10: 153-162, 1999
11. Durand B, Sperisen P, Emery P, Barras E, Zufferey M, Mach B, Reith W: RFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency. Embo J 16: 1045-1055, 1997
12. Harton JA, Ting JP: Class II transactivator: Mastering the art of major histocompatibility complex expression. Mol Cell Biol 20: 6185-6194, 2000
13. Collinge M, Pardi R, Bender JR: Class II transactivator-independent endothelial cell MHC class II gene activation induced by lymphocyte adhesion. J Immunol 161: 1589-1593, 1998
14. Muhlethaler-Mottet A, Otten LA, Steimle V, Mach B: Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. Embo J 16: 2851-2860, 1997
15. Lennon AM, Ottone C, Rigaud G, Deaven LL, Longmire J, Fellous M, Bono R, Alcaide-Loridan C: Isolation of a B-cell-specific promoter for the human class II transactivator. Immunogenetics 45: 266-273, 1997
16. Deffrennes V, Vedrenne J, Stolzenberg MC, Piskurich J, Barbieri G, Ting JP, Charron D, Alcaide-Loridan C: Constitutive expression of MHC class II genes in melanoma cell lines results from the transcription of class II transactivator abnormally initiated from its B cell-specific promoter. J Immunol 167: 98-106, 2001
17. Goodwin BL, Xi H, Tejiram R, Eason DD, Ghosh N, Wright KL, Nagarajan U, Boss JM, Blanck G: Varying functions of specific major histocompatibility class II transactivator promoter III and IV elements in melanoma cell lines. Cell Growth Differ 12: 327-335, 2001
18. Honey K, Rudensky A: The pIV-otal class II transactivator promoter regulates major histocompatibility complex class II expression in the thymus. J Exp Med 194: F15-F18, 2001
19. Waldburger JM, Suter T, Fontana A, Acha-Orbea H, Reith W: Selective abrogation of major histocompatibility complex class II expression on extrahematopoietic cells in mice lacking promoter IV of the class II transactivator gene. J Exp Med 194: 393-406, 2001
20. Folkman J, Haudenschild CC, Zetter BR: Long-term culture of capillary endothelial cells. Proc Natl Acad Sci USA 76: 5217-5221, 1979
21. Gerritsen ME, Shen CP, McHugh MC, Atkinson WJ, Kiely JM, Milstone DS, Luscinskas FW, Gimbrone MA Jr: Activation-dependent isolation and culture of murine pulmonary microvascular endothelium. Microcirculation 2: 151-163, 1995
22. McDouall RM, Batten P, McCormack A, Yacoub MH, Rose ML: MHC class II expression on human heart microvascular endothelial cells: Exquisite sensitivity to interferon-gamma and natural killer cells. Transplantation 64: 1175-1180, 1997
23. Kwak B, Mulhaupt F, Myit S, Mach F: Statins as a newly recognized type of immunomodulator. Nat Med 6: 1399-1402, 2000
24. Sadeghi MM, Tiglio A, Sadigh K, O'Donnell L, Collinge M, Pardi R, Bender JR: Inhibition of interferon-gamma-mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-CoA reductase inhibitors. Transplantation 71: 1262-1268, 2001
25. Lampson LA, Levy R: Two populations of Ia-like molecules on a human B cell line. J Immunol 125: 293-299, 1980
26. Watson AJ, DeMars R, Trowbridge IS, Bach FH: Detection of a novel human class II HLA antigen. Nature 304: 358-361, 1983
27. Spits H, Borst J, Giphart M, Coligan J, Terhorst C, De Vries JE: HLA-DC antigens can serve as recognition elements for human cytotoxic T lymphocytes. Eur J Immunol 14: 299-304, 1984
28. Salter RD, Howell DN, Cresswell P: Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics 21: 235-246, 1985
29. Muczynski KA, Anderson SK, Pious D: Discoordinate surface expression of IFN-gamma-induced HLA class II proteins in nonprofessional antigen-presenting cells with absence of DM and class II colocalization. J Immunol 160: 3207-3216, 1998
30. Ryan MJ, Johnson G, Kirk J, Fuerstenberg SM, Zager RA, Torok-Storb B: HK-2: An immortalized proximal tubule epithelial cell line from normal adult human kidney. Kidney Int 45: 48-57, 1994
31. Page C, Rose M, Yacoub M, Pigott R: Antigenic heterogeneity of vascular endothelium. Am J Pathol 141: 673-683, 1992
32. Kinjo T, Takashi M, Miyake K, Nagura H: Phenotypic heterogeneity of vascular endothelial cells in the human kidney. Cell Tissue Res 256: 27-34, 1989
33. Belloni PN, Tressler RJ: Microvascular endothelial cell heterogeneity: Interactions with leukocytes and tumor cells. Cancer Metastasis Rev 8: 353-389, 1990
34. Belloni PN, Carney DH, Nicolson GL: Organ-derived microvessel endothelial cells exhibit differential responsiveness to thrombin and other growth factors. Microvasc Res 43: 20-45, 1992
35. Lehmann I, Brylla E, Sittig D, Spanel-Borowski K, Aust G: Microvascular endothelial cells differ in their basal and tumour necrosis factor-alpha-regulated expression of adhesion molecules and cytokines. J Vasc Res 37: 408-416, 2000
36. Petzelbauer P, Bender JR, Wilson J, Pober JS: Heterogeneity of dermal microvascular endothelial cell antigen expression and cytokine responsiveness in situ and in cell culture. J Immunol 151: 5062-5072, 1993
37. Rupnick MA, Carey A, Williams SK: Phenotypic diversity in cultured cerebral microvascular endothelial cells. In Vitro Cell Dev Biol 24: 435-444, 1988
38. McDouall RM, Yacoub M, Rose ML: Isolation, culture, and characterization of MHC class II-positive microvascular endothelial cells from the human heart. Microvasc Res 51: 137-152, 1996
39. McDouall RM, Page CS, Hafizi S, Yacoub MH, Rose ML: Alloproliferation of purified CD4+ T cells to adult human heart endothelial cells, and study of second-signal requirements. Immunology 89: 220-226, 1996
40. Bishop GA, Hall BM, Duggin GG, Horvath JS, Sheil AG, Tiller DJ: Immunopathology of renal allograft rejection analyzed with monoclonal antibodies to mononuclear cell markers. Kidney Int 29: 708-717, 1986
41. Hall BM, Bishop GA, Duggin GG, Horvath JS, Philips J, Tiller DJ: Increased expression of HLA-DR antigens on renal tubular cells in renal transplants: Relevance to the rejection response. Lancet 2: 247-251, 1984
42. Muller CA, Markovic-Lipkovski J, Risler T, Bohle A, Muller GA: Expression of HLA-DQ, -DR, and -DP antigens in normal kidney and glomerulonephritis. Kidney Int 35: 116-124, 1989
43. Eason DD, Blanck G: High level class II trans-activator induction does not occur with transient activation of the IFN-gamma signaling pathway. J Immunol 166: 1041-1048, 2001
44. Kirk AD, Bollinger RR, Finn OJ: Rapid, comprehensive analysis of human cytokine mRNA and its application to the study of acute renal allograft rejection. Hum Immunol 43: 113-128, 1995
45. Leeuwenberg JF, Van Damme J, Meager T, Jeunhomme TM, Buurman WA: Effects of tumor necrosis factor on the interferon-gamma-induced major histocompatibility complex class II antigen expression by human endothelial cells. Eur J Immunol 18: 1469-1472, 1988
46. Wedgwood JF, Hatam L, Bonagura VR: Effect of interferon-gamma and tumor necrosis factor on the expression of class I and class II major histocompatibility molecules by cultured human umbilical vein endothelial cells. Cell Immunol 111: 1-9, 1988
47. Nikcevich KM, Piskurich JF, Hellendall RP, Wang Y, Ting JP: Differential selectivity of CIITA promoter activation by IFN-gamma and IRF-1 in astrocytes and macrophages: CIITA promoter activation is not affected by TNF-alpha. J Neuroimmunol 99: 195-204, 1999
48. Kutukculer N, Shenton BK, Clark K, Rigg KM, Forsythe JL, Kirby JA, Proud G, Taylor RM: Renal allograft rejection: the temporal relationship and predictive value of plasma TNF (alpha and beta), IFN-gamma and soluble ICAM-1. Transpl Int 8: 45-50, 1995
49. Katznelson S, Wilkinson AH, Kobashigawa JA, Wang XM, Chia D, Ozawa M, Zhong HP, Hirata M, Cohen AH, Teraski PI, et al: The effect of pravastatin on acute rejection after kidney transplantation - A pilot study. Transplantation 61: 1469-1474, 1996
50. Tuncer M, Suleymanlar G, Ersoy FF, Yakupoglu G: Comparison of the effects of simvastatin and pravastatin on acute rejection episodes in renal transplant patients. Transplant Proc 32: 622-625, 2000